Four-year, phase 3 data from APA 2024 show olanzapine/samidorphan provided consistent antipsychotic efficacy and weight-related safety in patients with either schizophrenia or bipolar I disorder.
Patients in the moderate and high disease activity cohorts reported significantly reduced health state utility values and HRQoL scores compared with the reference cohort.
https://www.hcplive.com/view/ra-significantly-impairs-physical-psychosocial-functioning
Extended follow-up of a phase 1/2 trial finds hydroxyurea dose optimization significantly improves clinical responses in children in sub-Saharan Africa with sickle cell.
https://www.hcplive.com/view/hydroxyurea-dose-escalation-effective-children-sickle-cell-anemia
These data shed light on several important findings related to perceptions of hair loss severity among specific groups with central centrifugal cicatricial alopecia and their QoL measures.
Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.
https://www.hcplive.com/view/copay-assistance-programs-for-adalimumab-biosimilars
Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.
Cardiorespiratory fitness showed the strongest association with gait parameters for women with fibromyalgia.
Results showed 46.45 and 72.74% increases in the global incidences of acute infection and HCV-related cirrhosis, respectively, in reproductive-age women.
https://www.hcplive.com/view/acute-hepatitis-c-hcv-related-cirrhosis-rise-reproductive-age-women
Patients in the Mediterranean diet group reported improvements in most fibromyalgia measures, including anxiety, fatigue, and disability scores.
https://www.hcplive.com/view/mediterranean-diet-improves-pain-qol-in-patients-with-fibromyalgia
Payal Kohli, MD, discusses how recent advancements have changed conversations surrounding modifiable cardiovascular risk and what it means for practitioners.
A nutritional supplement significantly improved the signs and symptoms of dry eye, including tear production and reduced ocular surface damage.
https://www.hcplive.com/view/daily-nutritional-supplement-achieves-improvement-dry-eye-symptoms
This analysis indicates that quantitative interstitial abnormalities may indicate alterations in lung tissue processes that can result in short- and long-term consequences as far as symptoms.
A new study highlights the importance of daily antioxidant intake for endometriosis-related RA.
Findings showed the light microscopy pattern of glomerular injury and the intensity of mesangial C3 deposition may refine the histological assessment of IgAN.
https://www.hcplive.com/view/study-suggests-variables-renal-risk-stratification-iga-nephropathy
The biosimilars month in review reflects ongoing efforts to address key challenges in rheumatic disease treatment.
https://www.hcplive.com/view/biosimilars-month-in-review-april-2024
This month's review focuses on digital technology use in ophthalmology, the association between vision impairment and mental health, and public health impacts in eye care.
https://www.hcplive.com/view/ophthalmology-month-in-review-april-2024
These survey results indicate that young adults tended to embrace misconceptions regarding sun protection and positive views of tanning.
Patients often rely on opioids a year before and a year after a diagnosis of ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis.
https://www.hcplive.com/view/patients-with-new-as-psa-ra-diagnosis-have-high-reliance-on-opioids
Findings suggest metformin and statins have a potective effect against HCC in patients with HCV who fail antiviral therapy.
Our April month in review for hematology breaks down the latest updates to the pipeline, mortality risk in people with sickle cell disease, and our newest multimedia offerings.
https://www.hcplive.com/view/hematology-month-in-review-april-2024
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
https://www.hcplive.com/view/cardiology-month-in-review-april-2024
At 6 months, patients treated with ReNu exhibited significant reductions in assessed knee pain and maintained patient function compared with controls.
https://www.hcplive.com/view/renu-achieves-primary-endpoint-in-phase-3-trial-for-knee-osteoarthritis
These data suggest vaping poses potential threats to the development of the brain and organs, with teenagers being a predominant target due to surges in use.
Experts discuss treating dry eye with procedural therapies, focusing on common in-office and at-home treatments.
https://www.hcplive.com/view/exploring-procedural-treatments-for-dry-eye
A new study found specific sociodemographic factors were linked to 76.4% lower odds of adhering to topical therapy for psoriasis.
This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.
https://www.hcplive.com/view/nephrology-month-in-review-april-2024
This month's review showcases the ongoing efforts to enhance patient care through innovative treatments and comprehensive management strategies.
https://www.hcplive.com/view/rheumatology-month-in-review-april-2024
An interim analysis of a phase 3 trial displays the effectiveness of prophylaxis with recombinant ADAMTS13, achieving approximately 100% of normal ADAMTS13 levels.
https://www.hcplive.com/view/recombinant-adamts13-prophylaxis-effective-approach-congenital-ttp
In this review of April 2024, the editorial team highlighted some of the biggest stories in the pulmonary health space, touching on topics such as air quality issues, asthma, and pneumonia.
https://www.hcplive.com/view/pulmonology-month-in-review-april-2024
Key opinion leaders in cardiology share insights on reducing LDL cholesterol to manage cardiovascular disease risk, educating patients not reaching goals, and implementing real-world clinical str...
https://www.hcplive.com/view/stricter-ldl-c-targets-explaining-goalpost-changes-to-patients